Conference dates: MARCH 20-22, 2023

Booth: 36

Location: Sheraton San Diego Marina, San Diego

Speaker session

Title: The new LSAXT and high-throughput SPR characterization of multi-specific antibodies

Speaker: Daniel Bedinger, PhD, Carterra

Date: Monday, Mar. 20, 2023

Time: 3:20–3:40 pm PT

Location: Driftwood 2

Abstract: The Carterra LSA platform is the leading platform for high-throughput kinetics and epitope analysis (HT-SPR technology) of mAbs and protein therapeutics. The new LSAXT platform has enhanced sensitivity, further extending the application space of HT-SPR to include molecule classes such as kinase inhibitors, PROTAC®S, and transient interactions like Fc Receptors.  Selection of bi and tri-specific binders often requires the screening of large combinatorial sample sets derived from panels of monospecific binders.  The Carterra LSA and LSAXT make analyzing the binding properties of these combinatorial panels straightforward and requires minimal amounts of mAb sample and antigen. The affinity of the binders to the targets can be measured in several assay formats and used to verify the independence and activity of each binding site for hundreds of clones. Along with the binding kinetics and specificity measurements, the LSA and LSAXT enable large scale epitope binning to ensure diverse sets of clones are being carried forward to functional evaluation.

Poster session

Poster Title: Large-scale characterization of drug candidates against transmembrane receptors using HT-SPR

Presenter: Daniel Bedinger, PhD, Carterra

Abstract: Transmembrane targets make up a substantial part of the overall “undruggable” therapeutic space that has recently garnered widespread interest. High-throughput surface plasmon resonance (HT-SPR) is a powerful technique that is transforming characterization workflows and enabling a greater breadth and depth of information for up to thousands of drug candidates. This workflow highlights opportunities to perform detailed binding characterization for up to thousands of drug candidates in parallel, accelerating the discovery of drug candidates targeting transmembrane receptors.